Teratomas a concern for stem cell-based therapies, EMA meeting hears
This article was originally published in Scrip
Executive Summary
The safety of stem cell-based therapies, particularly their potential to form teratomas, weighed heavily over a meeting held this week by the European Medicines Agency, which is trying to improve its limited regulatory know-how in a field that is fast evolving.